Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Change in Inventory (2022 - 2025)

Atara Biotherapeutics (ATRA) has disclosed Change in Inventory for 4 consecutive years, with -$10.7 million as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Change in Inventory fell 267.06% year-over-year to -$10.7 million, compared with a TTM value of -$10.5 million through Sep 2025, down 242.04%, and an annual FY2024 reading of $4.4 million, down 45.39% over the prior year.
  • Change in Inventory was -$10.7 million for Q1 2025 at Atara Biotherapeutics, down from $160000.0 in the prior quarter.
  • Across five years, Change in Inventory topped out at $6.4 million in Q1 2024 and bottomed at -$10.7 million in Q1 2025.
  • Average Change in Inventory over 4 years is $348500.0, with a median of $2.1 million recorded in 2022.
  • The sharpest move saw Change in Inventory skyrocketed 96.41% in 2023, then crashed 275.51% in 2024.
  • Year by year, Change in Inventory stood at $1.6 million in 2022, then surged by 96.41% to $3.1 million in 2023, then crashed by 94.86% to $160000.0 in 2024, then crashed by 6759.38% to -$10.7 million in 2025.
  • Business Quant data shows Change in Inventory for ATRA at -$10.7 million in Q1 2025, $160000.0 in Q4 2024, and -$4.8 million in Q3 2024.